KDR and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, novel candidate drugs for CML BC such as vascular endothelial growth factor receptor (VEGFR) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors were discovered from the DSRT analysis.